Skip to main content

Table 2 Comorbidities at enrolment

From: Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study

 

n (%)

N of patients with at least one comorbidity

171 (81.8)

Anxiety/depression

12 (5.7)

Arterial hypertension

103 (49.3)

Atherothrombotic disease, including coronary heart disease

27 (12.9)

Atrial fibrillation

9 (4.3)

Benign prostatic hypertrophy

25 (12.0)

Cerebrovascular disease (carotid stenosis, stroke)

13 (6.2)

Deep venous thrombosis (DVT)

1 (0.5)

Diabetes mellitus

45 (21.5)

Emphysema

8 (3.8)

Gastroesophageal reflux disease

49 (23.4)

Hypercholesterolaemia

17 (8.1)

Lung cancer

1 (0.5)

Peripheral arterial disease (symptomatic or ankle brachial index < 0.8)

2 (1.0)

Pulmonary hypertension

6 (2.9)

Renal insufficiency

5 (2.4)

Other

80 (38.3)

Previous myocardial infarction

23 (11.0)

  1. Percentages calculated out of total number of evaluable patients. A patient could have more than one comorbidity